GlassScriptPhysician profile
Brady R Walker
NPI 1346300530
$2,814.18
in general payments reported to CMS, 2019-2025
18 companies · $131 in 2025
The $131 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,472 · 2020: $86.65 · 2021: $16.76 · 2022: $3.82 · 2023: $56.36 · 2024: $47.51 · 2025: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $200 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $199.58 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urogpo LLC | $2,136.89 | 2019 | |
| Janssen Biotech, INC. | $286.34 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $60.23 | 2023-2024 | Gemtesa, Orgovyx |
| Tolmar, INC. | $59.57 | 2023-2025 | Eligard, Jatenzo, Rubraca |
| Astellas Pharma US INC | $38.75 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
| Abbvie INC. | $32.99 | 2025 | |
| Valencia Technologies Corporation | $27.81 | 2025 | Ecoin Device Kit |
| Bayer Healthcare Pharmaceuticals INC. | $22.36 | 2020 | |
| Amgen INC. | $22.27 | 2020 | |
| Novartis Pharmaceuticals Corporation | $18.98 | 2024 | |
| Coloplast Corp | $16.76 | 2021 | |
| Endo Pharmaceuticals INC. | $14.29 | 2019 | |
| Sun Pharmaceutical Industries INC. | $13.98 | 2019 | |
| Allergan, INC. | $11.72 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $8.54 | 2019 | |
| Travere Therapeutics, INC. | $7.64 | 2020-2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$340,127.23 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brady Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.